Alkermes plc. (ALKS) · Insider trading

What Alkermes's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.

Bought, 12 months

0 insiders, 0 trades

Sold, 12 months

$10.28M

7 insiders, 72% under a plan

Net, 12 months

−$10.28M

bought less sold

Latest filing

2026-10-09

filings read to 2026-10-19

Bought and sold at the market, by month

Two years. Purchases above the line, sales below, in dollars.

Bought Sold Largest month: $12.09M

Who traded, two years

Insider	Bought	Sold	Trades	Last trade	Holds after
Hopkinson Craig C.EVP R&D, Chief Medical Officer	–	$23.80M	26	2026-09-01	65,389
snyderman nancy lynn MDDirector	–	$2.24M	1	2026-08-03	15,395
Cooke ShaneDirector	–	$2.12M	2	2026-02-02	135,857
Parisi Samuel JosephVP, Finance (Interim PAO)	–	$1.13M	5	2026-05-29	7,717
Nichols Christian ToddSVP, Chief Commercial Officer	–	$914,925	6	2026-08-17	102,857
Gaffin David JosephEVP, CLO, Alkermes, Inc.	–	$735,332	9	2026-10-02	221,388
Wright Christopher IDirector	–	$90,200	1	2026-06-12	25,680
Laurencin Cato TDirector	–	$85,708	1	2024-12-09	23,013

Open-market purchases and sales

Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.

Date	Insider	Trade	Shares	Price	Value	Holds after	Filing
2026-10-02	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Saleplan	2,034	41.03	$83,455	221,388	Form 4
2026-09-03	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Saleplan	2,034	48.01	$97,652	223,422	Form 4
2026-09-01	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	9,000	46.99	$422,910	65,389	Form 4
2026-08-17	Nichols Christian ToddSVP, Chief Commercial Officer	Saleplan	6,912	49.19	$340,001	102,857	Form 4
2026-08-17	Nichols Christian ToddSVP, Chief Commercial Officer	Saleplan	664	49.65	$32,968	102,193	Form 4
2026-08-03	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Saleplan	2,034	48.58	$98,812	225,456	Form 4
2026-08-03	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	9,000	48.58	$437,220	69,389	Form 4
2026-08-03	snyderman nancy lynn MDDirector	Sale	44,472	50.35	$2.24M	15,395	Form 4
2026-07-06	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Saleplan	2,034	54.03	$109,897	227,490	Form 4
2026-07-01	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	8,300	51.46	$427,118	74,089	Form 4
2026-07-01	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	700	52.13	$36,491	73,389	Form 4
2026-06-12	Wright Christopher IDirector	Saleplan	2,000	45.10	$90,200	25,680	Form 4
2026-06-04	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Saleplan	2,034	43.05	$87,564	229,524	Form 4
2026-06-01	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	9,000	41.67	$375,030	77,389	Form 4
2026-05-29	Parisi Samuel JosephVP, Finance (Interim PAO)	Sale	16,217	42.36	$686,952	7,717	Form 4
2026-05-04	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Saleplan	2,034	33.20	$67,529	231,558	Form 4
2026-05-01	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	9,000	33.40	$300,600	81,389	Form 4
2026-04-06	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Saleplan	2,034	34.57	$70,315	233,592	Form 4
2026-04-01	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	9,000	35.51	$319,590	85,389	Form 4
2026-03-03	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Saleplan	2,034	29.76	$60,532	235,626	Form 4
2026-03-02	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Saleplan	2,034	29.29	$59,576	237,660	Form 4
2026-03-02	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	9,000	29.72	$267,480	89,389	Form 4
2026-03-02	Nichols Christian ToddSVP, Chief Commercial Officer	Saleplan	6,000	30.00	$180,000	109,769	Form 4
2026-03-02	Parisi Samuel JosephVP, Finance (Interim PAO)	Saleplan	6,890	29.29	$201,808	7,717	Form 4
2026-02-02	Cooke ShaneDirector	Saleplan	29,087	34.34	$998,848	135,857	Form 4
2026-02-02	Cooke ShaneDirector	Saleplan	32,113	34.78	$1.12M	103,744	Form 4
2026-02-02	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	5,000	34.24	$171,200	61,740	Form 4
2026-02-02	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	4,000	33.54	$134,160	57,740	Form 4
2026-01-08	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	5,000	30.00	$150,000	61,740	Form 4
2026-01-02	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	4,000	28.00	$112,000	61,740	Form 4
2025-12-03	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	3,748	30.00	$112,440	65,740	Form 4
2025-12-01	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	4,000	29.30	$117,200	65,740	Form 4
2025-11-03	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	9,000	30.38	$273,420	69,740	Form 4
2025-10-15	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	9,000	31.53	$283,770	73,740	Form 4
2025-06-10	Nichols Christian ToddSVP, Chief Commercial Officer	Saleplan	3,334	31.09	$103,654	86,208	Form 4
2025-06-09	Nichols Christian ToddSVP, Chief Commercial Officer	Saleplan	3,333	31.95	$106,489	89,542	Form 4
2025-02-28	Parisi Samuel JosephVP, Finance (Interim PAO)	Saleplan	1,938	34.00	$65,892	7,717	Form 4
2025-02-25	Parisi Samuel JosephVP, Finance (Interim PAO)	Saleplan	3,743	35.26	$131,978	7,717	Form 4
2025-02-20	Parisi Samuel JosephVP, Finance (Interim PAO)	Saleplan	1,327	35.69	$47,361	7,717	Form 4
2025-02-13	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	35,586	34.02	$1.21M	166,708	Form 4

11 more

2025-02-13	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	108,833	36.02	$3.92M	57,875	Form 4
2025-02-12	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	171,813	32.69	$5.62M	90,983	Form 4
2025-02-12	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	33,108	33.27	$1.10M	57,875	Form 4
2025-01-30	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	100,918	32.05	$3.23M	44,290	Form 4
2024-12-09	Laurencin Cato TDirector	Saleplan	2,691	31.85	$85,708	23,013	Form 4
2024-12-09	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	61,151	32.07	$1.96M	47,576	Form 4
2024-12-05	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	9,221	31.50	$290,462	59,730	Form 4
2024-12-04	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	14,349	30.77	$441,519	68,951	Form 4
2024-11-27	Nichols Christian ToddSVP, Chief Commercial Officer	Saleplan	5,208	29.15	$151,813	60,703	Form 4
2024-11-11	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	58,996	30.08	$1.77M	83,300	Form 4
2024-11-06	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Saleplan	10,471	29.53	$309,209	99,238	Form 4

Grants, exercises and other transactions

Pay, tax and paperwork rather than a choice to trade at the market price. Two years.

99 × option exercise78 × shares withheld for tax11 × grant or award

Show them

Date	Insider	What	Shares	Price	Holds after	Filing
2026-10-08	Reed JoshuaSVP, Chief Financial Officer	Option exercise M	+9,164	–	9,164	Form 4
2026-10-08	Reed JoshuaSVP, Chief Financial Officer	Shares withheld for tax F	−4,069	40.11	5,095	Form 4
2026-09-01	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+5,000	24.59	74,389	Form 4
2026-08-03	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+104	19.34	73,493	Form 4
2026-08-03	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+4,896	24.59	78,389	Form 4
2026-08-03	snyderman nancy lynn MDDirector	Option exercise M	+27,948	46.72	43,343	Form 4
2026-08-03	snyderman nancy lynn MDDirector	Option exercise M	+16,524	46.72	59,867	Form 4
2026-07-01	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+5,000	19.34	82,389	Form 4
2026-06-01	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+5,000	19.34	86,389	Form 4
2026-05-29	Parisi Samuel JosephVP, Finance (Interim PAO)	Option exercise M	+3,392	20.03	11,109	Form 4
2026-05-29	Parisi Samuel JosephVP, Finance (Interim PAO)	Option exercise M	+12,825	19.34	23,934	Form 4
2026-05-21	Cooke ShaneDirector	Option exercise M	+6,142	–	109,886	Form 4
2026-05-21	Cooke ShaneDirector	Shares withheld for tax F	−3,207	36.95	106,679	Form 4
2026-05-21	Gaynor RichardDirector	Option exercise M	+6,142	–	37,226	Form 4
2026-05-21	Gaynor RichardDirector	Shares withheld for tax F	−1,475	36.95	35,751	Form 4
2026-05-21	Laurencin Cato TDirector	Option exercise M	+6,142	–	35,244	Form 4
2026-05-21	Laurencin Cato TDirector	Shares withheld for tax F	−1,475	36.95	33,769	Form 4
2026-05-21	Lurker NancyDirector	Option exercise M	+6,142	–	19,697	Form 4
2026-05-21	Lurker NancyDirector	Shares withheld for tax F	−1,475	36.95	18,222	Form 4
2026-05-21	McKeon Brian PDirector	Option exercise M	+6,142	–	40,011	Form 4
2026-05-21	McKeon Brian PDirector	Shares withheld for tax F	−1,475	36.95	38,536	Form 4
2026-05-21	snyderman nancy lynn MDDirector	Option exercise M	+6,142	–	16,870	Form 4
2026-05-21	snyderman nancy lynn MDDirector	Shares withheld for tax F	−1,475	36.95	15,395	Form 4
2026-05-21	Wilson Frank AndersDirector	Option exercise M	+6,142	–	37,226	Form 4
2026-05-21	Wilson Frank AndersDirector	Shares withheld for tax F	−1,475	36.95	35,751	Form 4
2026-05-21	Wright Christopher IDirector	Option exercise M	+6,142	–	29,155	Form 4
2026-05-21	Wright Christopher IDirector	Shares withheld for tax F	−1,475	36.95	27,680	Form 4
2026-05-01	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+5,000	19.34	90,389	Form 4
2026-04-11	Lurker NancyDirector	Option exercise M	+3,751	–	14,456	Form 4
2026-04-11	Lurker NancyDirector	Shares withheld for tax F	−901	33.36	13,555	Form 4
2026-04-01	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+5,000	19.34	94,389	Form 4
2026-03-02	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+5,000	19.34	98,389	Form 4
2026-02-26	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Option exercise M	+6,866	–	242,743	Form 4
2026-02-26	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Shares withheld for tax F	−3,049	30.73	239,694	Form 4
2026-02-26	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+6,866	–	96,438	Form 4
2026-02-26	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Shares withheld for tax F	−3,049	30.73	93,389	Form 4
2026-02-26	Jackson Blair CurtisEVP, Chief Operating Officer	Option exercise M	+8,322	–	245,003	Form 4
2026-02-26	Jackson Blair CurtisEVP, Chief Operating Officer	Shares withheld for tax F	−3,695	30.73	241,308	Form 4
2026-02-26	Nichols Christian ToddSVP, Chief Commercial Officer	Option exercise M	+5,410	–	118,172	Form 4
2026-02-26	Nichols Christian ToddSVP, Chief Commercial Officer	Shares withheld for tax F	−2,403	30.73	115,769	Form 4
2026-02-26	Parisi Samuel JosephVP, Finance (Interim PAO)	Option exercise M	+2,747	–	15,415	Form 4
2026-02-26	Parisi Samuel JosephVP, Finance (Interim PAO)	Shares withheld for tax F	−808	30.73	14,607	Form 4
2026-02-23	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Option exercise M	+7,689	–	239,291	Form 4
2026-02-23	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Shares withheld for tax F	−3,414	32.19	235,877	Form 4
2026-02-23	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+7,689	–	92,986	Form 4
2026-02-23	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Shares withheld for tax F	−3,414	32.19	89,572	Form 4
2026-02-23	Jackson Blair CurtisEVP, Chief Operating Officer	Option exercise M	+8,738	–	240,561	Form 4
2026-02-23	Jackson Blair CurtisEVP, Chief Operating Officer	Shares withheld for tax F	−3,880	32.19	236,681	Form 4
2026-02-23	Nichols Christian ToddSVP, Chief Commercial Officer	Option exercise M	+6,407	–	115,607	Form 4
2026-02-23	Nichols Christian ToddSVP, Chief Commercial Officer	Shares withheld for tax F	−2,845	32.19	112,762	Form 4
2026-02-23	Parisi Samuel JosephVP, Finance (Interim PAO)	Option exercise M	+2,283	–	13,340	Form 4
2026-02-23	Parisi Samuel JosephVP, Finance (Interim PAO)	Shares withheld for tax F	−672	32.19	12,668	Form 4
2026-02-19	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Option exercise M	+7,673	–	235,009	Form 4
2026-02-19	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Shares withheld for tax F	−3,407	32.00	231,602	Form 4
2026-02-19	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+7,673	–	88,704	Form 4
2026-02-19	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Shares withheld for tax F	−3,407	32.00	85,297	Form 4
2026-02-19	Jackson Blair CurtisEVP, Chief Operating Officer	Option exercise M	+9,300	–	235,953	Form 4
2026-02-19	Jackson Blair CurtisEVP, Chief Operating Officer	Shares withheld for tax F	−4,130	32.00	231,823	Form 4
2026-02-19	Nichols Christian ToddSVP, Chief Commercial Officer	Option exercise M	+6,045	–	111,477	Form 4
2026-02-19	Nichols Christian ToddSVP, Chief Commercial Officer	Shares withheld for tax F	−2,277	32.00	109,200	Form 4
2026-02-19	Parisi Samuel JosephVP, Finance (Interim PAO)	Option exercise M	+2,991	–	12,036	Form 4
2026-02-19	Parisi Samuel JosephVP, Finance (Interim PAO)	Shares withheld for tax F	−979	32.00	11,057	Form 4
2026-02-18	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Option exercise M	+6,355	–	229,462	Form 4
2026-02-18	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Shares withheld for tax F	−2,126	32.02	227,336	Form 4
2026-02-18	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+8,897	–	84,535	Form 4
2026-02-18	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Shares withheld for tax F	−3,504	32.02	81,031	Form 4
2026-02-18	Jackson Blair CurtisEVP, Chief Operating Officer	Option exercise M	+8,897	–	230,449	Form 4
2026-02-18	Jackson Blair CurtisEVP, Chief Operating Officer	Shares withheld for tax F	−3,796	32.02	226,653	Form 4
2026-02-18	Nichols Christian ToddSVP, Chief Commercial Officer	Option exercise M	+6,355	–	107,301	Form 4
2026-02-18	Nichols Christian ToddSVP, Chief Commercial Officer	Shares withheld for tax F	−1,869	32.02	105,432	Form 4
2026-02-18	Parisi Samuel JosephVP, Finance (Interim PAO)	Option exercise M	+2,034	–	9,751	Form 4
2026-02-18	Parisi Samuel JosephVP, Finance (Interim PAO)	Shares withheld for tax F	−706	32.02	9,045	Form 4
2026-02-05	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Grant or award A	+25,352	–	230,726	Form 4
2026-02-05	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Shares withheld for tax F	−7,619	33.55	223,107	Form 4
2026-02-05	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Grant or award A	+25,352	–	83,092	Form 4
2026-02-05	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Shares withheld for tax F	−7,454	33.55	75,638	Form 4
2026-02-05	Jackson Blair CurtisEVP, Chief Operating Officer	Grant or award A	+28,810	–	230,178	Form 4
2026-02-05	Jackson Blair CurtisEVP, Chief Operating Officer	Shares withheld for tax F	−8,626	33.55	221,552	Form 4
2026-02-05	Nichols Christian ToddSVP, Chief Commercial Officer	Grant or award A	+21,127	–	107,335	Form 4
2026-02-05	Nichols Christian ToddSVP, Chief Commercial Officer	Shares withheld for tax F	−6,389	33.55	100,946	Form 4
2026-02-05	Pops Richard FDirector, Director and CEO, Alkermes plc	Grant or award A	+149,580	–	1,439,970	Form 4
2026-02-05	Pops Richard FDirector, Director and CEO, Alkermes plc	Shares withheld for tax F	−62,230	33.55	1,377,740	Form 4
2026-02-02	Cooke ShaneDirector	Option exercise M	+61,200	31.64	164,944	Form 4
2026-02-02	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+5,000	19.34	66,740	Form 4
2026-01-08	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+5,000	19.34	66,740	Form 4
2025-12-03	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+3,748	19.34	69,488	Form 4
2025-11-03	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+5,000	19.34	78,740	Form 4
2025-10-15	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+5,000	19.34	82,740	Form 4
2025-08-03	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Option exercise M	+2,014	–	206,269	Form 4
2025-08-03	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Shares withheld for tax F	−895	26.55	205,374	Form 4
2025-06-08	Wright Christopher IDirector	Option exercise M	+3,301	–	23,806	Form 4
2025-06-08	Wright Christopher IDirector	Shares withheld for tax F	−793	31.71	23,013	Form 4
2025-05-31	Cooke ShaneDirector	Option exercise M	+8,013	–	107,919	Form 4
2025-05-31	Cooke ShaneDirector	Shares withheld for tax F	−4,175	30.61	103,744	Form 4
2025-05-31	Gaynor RichardDirector	Option exercise M	+8,013	–	33,008	Form 4
2025-05-31	Gaynor RichardDirector	Shares withheld for tax F	−1,924	30.61	31,084	Form 4
2025-05-31	Laurencin Cato TDirector	Option exercise M	+8,013	–	31,026	Form 4
2025-05-31	Laurencin Cato TDirector	Shares withheld for tax F	−1,924	30.61	29,102	Form 4
2025-05-31	Lurker NancyDirector	Option exercise M	+8,013	–	12,629	Form 4
2025-05-31	Lurker NancyDirector	Shares withheld for tax F	−1,924	30.61	10,705	Form 4
2025-05-31	McKeon Brian PDirector	Option exercise M	+8,013	–	35,793	Form 4
2025-05-31	McKeon Brian PDirector	Shares withheld for tax F	−1,924	30.61	33,869	Form 4
2025-05-31	snyderman nancy lynn MDDirector	Option exercise M	+8,013	–	12,652	Form 4
2025-05-31	snyderman nancy lynn MDDirector	Shares withheld for tax F	−1,924	30.61	10,728	Form 4
2025-05-31	Wilson Frank AndersDirector	Option exercise M	+8,013	–	33,008	Form 4
2025-05-31	Wilson Frank AndersDirector	Shares withheld for tax F	−1,924	30.61	31,084	Form 4
2025-05-31	Wright Christopher IDirector	Option exercise M	+8,013	–	22,429	Form 4
2025-05-31	Wright Christopher IDirector	Shares withheld for tax F	−1,924	30.61	20,505	Form 4
2025-04-11	Lurker NancyDirector	Option exercise M	+2,323	–	2,323	Form 4
2025-04-11	Lurker NancyDirector	Shares withheld for tax F	−558	27.00	1,765	Form 4
2025-04-11	Lurker NancyDirector	Option exercise M	+3,752	–	5,517	Form 4
2025-04-11	Lurker NancyDirector	Shares withheld for tax F	−901	27.00	4,616	Form 4
2025-02-26	Brown Iain MichaelSVP, Chief Financial Officer	Option exercise M	+5,617	–	150,690	Form 4
2025-02-26	Brown Iain MichaelSVP, Chief Financial Officer	Shares withheld for tax F	−2,494	34.80	148,196	Form 4
2025-02-26	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Option exercise M	+6,866	–	207,304	Form 4
2025-02-26	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Shares withheld for tax F	−3,049	34.80	204,255	Form 4
2025-02-26	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+6,866	–	80,789	Form 4
2025-02-26	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Shares withheld for tax F	−3,049	34.80	77,740	Form 4
2025-02-26	Jackson Blair CurtisEVP, Chief Operating Officer	Option exercise M	+8,322	–	205,063	Form 4
2025-02-26	Jackson Blair CurtisEVP, Chief Operating Officer	Shares withheld for tax F	−3,695	34.80	201,368	Form 4
2025-02-26	Nichols Christian ToddSVP, Chief Commercial Officer	Option exercise M	+5,409	–	95,277	Form 4
2025-02-26	Nichols Christian ToddSVP, Chief Commercial Officer	Shares withheld for tax F	−2,402	34.80	92,875	Form 4
2025-02-26	Parisi Samuel JosephVP, Finance (Interim PAO)	Option exercise M	+2,746	–	10,463	Form 4
2025-02-26	Parisi Samuel JosephVP, Finance (Interim PAO)	Shares withheld for tax F	−808	34.80	9,655	Form 4
2025-02-23	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+7,689	–	77,337	Form 4
2025-02-23	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Shares withheld for tax F	−3,414	35.32	73,923	Form 4
2025-02-23	Nichols Christian ToddSVP, Chief Commercial Officer	Option exercise M	+6,408	–	92,714	Form 4
2025-02-23	Nichols Christian ToddSVP, Chief Commercial Officer	Shares withheld for tax F	−2,846	35.32	89,868	Form 4
2025-02-23	Brown Iain MichaelSVP, Chief Financial Officer	Option exercise M	+5,825	–	147,660	Form 4
2025-02-23	Brown Iain MichaelSVP, Chief Financial Officer	Shares withheld for tax F	−2,587	35.32	145,073	Form 4
2025-02-23	Parisi Samuel JosephVP, Finance (Interim PAO)	Option exercise M	+2,284	–	12,132	Form 4
2025-02-23	Parisi Samuel JosephVP, Finance (Interim PAO)	Shares withheld for tax F	−672	35.32	11,460	Form 4
2025-02-23	Jackson Blair CurtisEVP, Chief Operating Officer	Option exercise M	+8,738	–	200,621	Form 4
2025-02-23	Jackson Blair CurtisEVP, Chief Operating Officer	Shares withheld for tax F	−3,880	35.32	196,741	Form 4
2025-02-23	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Option exercise M	+7,689	–	203,852	Form 4
2025-02-23	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Shares withheld for tax F	−3,414	35.32	200,438	Form 4
2025-02-22	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+12,279	–	75,100	Form 4
2025-02-22	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Shares withheld for tax F	−5,452	35.32	69,648	Form 4
2025-02-22	Nichols Christian ToddSVP, Chief Commercial Officer	Option exercise M	+7,109	–	89,463	Form 4
2025-02-22	Nichols Christian ToddSVP, Chief Commercial Officer	Shares withheld for tax F	−3,157	35.32	86,306	Form 4
2025-02-22	Brown Iain MichaelSVP, Chief Financial Officer	Option exercise M	+7,109	–	144,989	Form 4
2025-02-22	Brown Iain MichaelSVP, Chief Financial Officer	Shares withheld for tax F	−3,154	35.32	141,835	Form 4
2025-02-22	Parisi Samuel JosephVP, Finance (Interim PAO)	Option exercise M	+3,114	–	10,831	Form 4
2025-02-22	Parisi Samuel JosephVP, Finance (Interim PAO)	Shares withheld for tax F	−983	35.32	9,848	Form 4
2025-02-22	Jackson Blair CurtisEVP, Chief Operating Officer	Option exercise M	+9,694	–	196,188	Form 4
2025-02-22	Jackson Blair CurtisEVP, Chief Operating Officer	Shares withheld for tax F	−4,305	35.32	191,883	Form 4
2025-02-22	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Option exercise M	+7,432	–	199,463	Form 4
2025-02-22	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Shares withheld for tax F	−3,300	35.32	196,163	Form 4
2025-02-18	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+8,896	–	66,771	Form 4
2025-02-18	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Shares withheld for tax F	−3,950	35.90	62,821	Form 4
2025-02-18	Jackson Blair CurtisEVP, Chief Operating Officer	Option exercise M	+8,896	–	190,444	Form 4
2025-02-18	Jackson Blair CurtisEVP, Chief Operating Officer	Shares withheld for tax F	−3,950	35.90	186,494	Form 4
2025-02-18	Brown Iain MichaelSVP, Chief Financial Officer	Option exercise M	+6,354	–	139,749	Form 4
2025-02-18	Brown Iain MichaelSVP, Chief Financial Officer	Shares withheld for tax F	−1,869	35.90	137,880	Form 4
2025-02-18	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Option exercise M	+6,354	–	194,853	Form 4
2025-02-18	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Shares withheld for tax F	−2,822	35.90	192,031	Form 4
2025-02-18	Nichols Christian ToddSVP, Chief Commercial Officer	Option exercise M	+6,354	–	84,223	Form 4
2025-02-18	Nichols Christian ToddSVP, Chief Commercial Officer	Shares withheld for tax F	−1,869	35.90	82,354	Form 4
2025-02-18	Parisi Samuel JosephVP, Finance (Interim PAO)	Option exercise M	+2,033	–	9,750	Form 4
2025-02-18	Parisi Samuel JosephVP, Finance (Interim PAO)	Shares withheld for tax F	−706	35.90	9,044	Form 4
2025-02-13	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+108,833	31.93	166,708	Form 4
2025-02-13	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+35,586	24.59	202,294	Form 4
2025-02-12	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+87,566	20.03	151,166	Form 4
2025-02-12	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+111,630	19.34	262,796	Form 4
2025-02-06	Brown Iain MichaelSVP, Chief Financial Officer	Grant or award A	+24,565	–	140,909	Form 4
2025-02-06	Brown Iain MichaelSVP, Chief Financial Officer	Shares withheld for tax F	−7,514	31.39	133,395	Form 4
2025-02-06	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Grant or award A	+32,350	–	198,251	Form 4
2025-02-06	Gaffin David JosephEVP, CLO, Alkermes, Inc.	Shares withheld for tax F	−9,752	31.39	188,499	Form 4
2025-02-06	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Grant or award A	+34,393	–	78,683	Form 4
2025-02-06	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Shares withheld for tax F	−15,083	31.39	63,600	Form 4
2025-02-06	Jackson Blair CurtisEVP, Chief Operating Officer	Grant or award A	+34,393	–	192,195	Form 4
2025-02-06	Jackson Blair CurtisEVP, Chief Operating Officer	Shares withheld for tax F	−10,647	31.39	181,548	Form 4
2025-02-06	Nichols Christian ToddSVP, Chief Commercial Officer	Grant or award A	+24,565	–	85,268	Form 4
2025-02-06	Nichols Christian ToddSVP, Chief Commercial Officer	Shares withheld for tax F	−7,399	31.39	77,869	Form 4
2025-02-06	Pops Richard FDirector, Director and CEO, Alkermes plc	Grant or award A	+190,640	–	1,370,315	Form 4
2025-02-06	Pops Richard FDirector, Director and CEO, Alkermes plc	Shares withheld for tax F	−79,925	31.39	1,290,390	Form 4
2025-01-30	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+29,156	20.03	76,732	Form 4
2025-01-30	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+26,589	19.34	103,321	Form 4
2025-01-30	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+23,542	24.59	126,863	Form 4
2025-01-30	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+18,345	26.82	145,208	Form 4
2024-12-09	Laurencin Cato TDirector	Option exercise M	+2,691	22.52	25,704	Form 4
2024-12-09	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+12,452	20.03	72,182	Form 4
2024-12-09	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+12,090	19.34	84,272	Form 4
2024-12-09	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+12,044	24.59	96,316	Form 4
2024-12-09	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+12,411	26.82	108,727	Form 4
2024-12-08	Laurencin Cato TDirector	Option exercise M	+4,163	–	23,971	Form 4
2024-12-08	Laurencin Cato TDirector	Shares withheld for tax F	−958	31.46	23,013	Form 4
2024-11-11	Hopkinson Craig C.EVP R&D, Chief Medical Officer	Option exercise M	+43,058	20.03	142,296	Form 4

How to read it

Buy, sale: Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
Plan: A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
Holds after: The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
Value: Shares times the price the form reports, which is often an average over several fills on the day.

Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.

Alkermes's scores and multiples ›